TET2 Mutations in Patients With AML Do Not Affect Outcome

Share this content:
(ChemotherapyAdvisor) – A study of patients with acute myeloid leukemia (AML) has identified TET2 mutations in 7.6% that did not affect response to therapy or survival, investigators concluded in the Journal of Clinical Oncology online March 19.

Recently, the tet oncogene family member 2 (TET2) gene was identified to be mutated in myeloid disorders, including AML; however, to date, its clinical relevance remains uncertain. “Thus, we explored the frequency, gene expression pattern, and clinical impact of TET2 mutations in a large cohort of patients with AML in the context of other AML-associated aberrations,” Gaidzik et al. noted.

They conducted a comprehensive genetic and clinical analysis of 783 patients ages 18 to 60 years enrolled in the prospective German-Austrian AML Study Group multicenter treatment trial AML HD98A, which was open from January 1998 until December 2004.

A total of 66 TET2 mutations were found in 60 patients, including missense in 37, frameshift in 16, and nonsense in 13, which, with one exception, were all heterozygous. The TET2 mutations were not associated with a clinical phenotype and were almost mutually exclusive with isocitrate dehydrogenase mutations (IDH) mutations (P<0.001).

These findings support recent data “on a common mechanism of action that might obscure the impact of TET2 mutations if compared against all other patients with AML,” they concluded, adding that the impact of TET2 mutations “will need to be reevaluated in the light of additional gene mutations that influenced epigenetic regulation in AML.”

Abstract

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs